VISEN Pharmaceuticals (FRA:T06) Interest Expense: €-0.39 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:T06 VISEN Pharmaceuticals FRA:T06
7 GF Score
Price €2.06
! 5 Warning Signs
View Full Analysis

What is VISEN Pharmaceuticals Interest Expense?

VISEN Pharmaceuticals FRA:T06 7 Interest Expense is €-0.39 Mil as of Jun. 2026. GuruFocus rates FRA:T06 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. VISEN Pharmaceuticals's interest expense for the six months ended in Jun. 2026 was € -0.26 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.39 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. VISEN Pharmaceuticals's Operating Income for the six months ended in Jun. 2026 was € -11.33 Mil. VISEN Pharmaceuticals's Interest Expense for the six months ended in Jun. 2026 was € -0.26 Mil. VISEN Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

VISEN Pharmaceuticals  (FRA:T06) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

VISEN Pharmaceuticals's Interest Expense for the six months ended in Jun. 2026 was €-0.26 Mil. Its Operating Income for the six months ended in Jun. 2026 was €-11.33 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2026 was €0.48 Mil.

VISEN Pharmaceuticals's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

VISEN Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

VISEN Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for VISEN Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VISEN Pharmaceuticals Interest Expense Chart

VISEN Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Interest Expense
-0.08 -0.04 -0.02 -0.13

VISEN Pharmaceuticals Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Interest Expense Get a 7-Day Free Trial -0.01 -0.01 -0.01 -0.13 -0.26
FRA:T06
7GF Score
VISEN Pharmaceuticals FRA:T06
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VISEN Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.39 Mil mean?
VISEN Pharmaceuticals (FRA:T06) has a Interest Expense of €-0.39 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on VISEN Pharmaceuticals and its competitors.
Is VISEN Pharmaceuticals' Interest Expense too high?
VISEN Pharmaceuticals' current Interest Expense is €-0.39 Mil. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' Interest Expense compare to ZTS?
VISEN Pharmaceuticals' Interest Expense of €-0.39 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on VISEN Pharmaceuticals and its competitors. VISEN Pharmaceuticals's current Interest Expense is €-0.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current Interest Expense of €-0.39 Mil. The current Interest Expense is €-0.39 Mil. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current Interest Expense is €-0.39 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VISEN Pharmaceuticals Business Description

Other Exchanges 02561:Hong Kong
Address 69 Jiuzhang Road, Suite 3-108, Floor 3, Building B, Hengtai Lixiang Chuangxin Tower, Suzhou, CHN
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score

Get the complete analysis for FRA:T06

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.06
Price